Since July 1, Medicare's "Bridge" program has offered eligible beneficiaries the GLP-1 weight-loss drugs Wegovy, Zepbound, and Foundayo for $50 a month, a striking price for medications that can otherwise run many hundreds of dollars. That figure is the headline most patients will hear and hold onto. But a physician writing in STAT argues that the program may fail the very people it is meant to help, not because of its price or its purpose, but because of the administrative machinery wrapped around it.
The concern that a hard-to-navigate benefit will leave people behind is a familiar one, and a real one. But there is a subtler danger here that the usual access debate tends to miss, and it is specific to what Bridge actually is: a temporary program whose usage will be read as a verdict on whether broad coverage is worth making permanent. A program this burdensome could end up generating the very evidence used to kill the thing it was supposed to lead to.
What Bridge offers, and what it demands
The offer is genuinely meaningful. Eligible beneficiaries can obtain these drugs for $50 a month, a price that puts them within reach for many people who could not otherwise afford them. The difficulty lies in everything behind that number. Eligibility runs through a detailed checklist of body-mass-index thresholds, particular combinations of chronic conditions, and prior treatment histories, and what looks to a patient like a simple prescription sets off a long process.
That process includes verifying the clinical criteria, documenting obesity-related conditions and past weight-management efforts, submitting insurer-specific paperwork, obtaining prior authorizations, and filing appeals when requests are denied, alongside the counseling a clinician owes any patient starting these drugs about side effects, dose escalation, and the likelihood of long-term use. The $50 turns out to be the easy part. The paperwork is the hard part, and the paperwork is where the program will succeed or fail.
The real constraint isn't price or demand. It's primary care's capacity
It is worth being precise about what actually limits a program like this, because it is none of the obvious things. It is not the drug price, which at $50 is low. It is not patient demand, which by every account is surging. The binding constraint is the administrative capacity of primary care to absorb all that documentation, and that capacity is a fixed, scarce, and already badly overstretched resource.
Primary care is stretched thin, contending with workforce shortages, burnout, and sagging morale, and the Bridge workload lands squarely on it, in the author's account rivaling the clinical work itself. The program implicitly assumes that primary care has spare capacity to take this on. It does not. So when the paperwork exceeds what a practice can sustain, the practice does the only thing it can: it rations itself. Some will simply decline to help with Bridge enrollment, steering patients toward manufacturer programs, telehealth services, or self-navigation. When that happens, access collapses not at the level of the patient but at the level of the provider, regardless of how many patients qualify or how badly they want the drug. A benefit no one has the staff to deliver is not, in practice, a benefit.
The collapse isn't random
When it does collapse, it does not collapse evenly. Navigating a complicated program rewards patients who have time, health literacy, and the capacity for persistent self-advocacy, and it leaves behind those who have less of each, who are frequently the patients at highest risk to begin with. And once practices start opting out, access comes to depend on a given clinic's administrative bandwidth as much as on a patient's medical need, producing a two-tier system. As the author puts it, a benefit that exists on paper is altogether different from access in practice. The same dynamic shows up in Medicaid, where eligible people lose coverage they qualify for because they cannot get through the process, and it applies to Bridge with full force.
The subtler danger: the friction corrupts the evidence
Here is the point that makes this more than a familiar access story. Bridge is temporary by design. It was built as a bridge toward Balance, a permanent program that would have folded GLP-1 coverage into Medicare Part D for the millions who might benefit. But the administration canceled Balance and extended Bridge instead, through the end of 2027, which leaves Bridge as a bridge to nowhere in particular, and leaves its usage to be read as a signal about whether permanent, broad coverage is worth building at all.
And this is the trap. Low uptake caused by a burdensome program looks exactly like low uptake caused by low demand. The two are indistinguishable in the data. If relatively few people manage to navigate Bridge successfully, policymakers can read that as evidence that beneficiaries do not really want these drugs, when the true cause is that the program was too hard to use. The administrative design, in other words, does not merely determine who gets the medication. It determines what the experiment appears to show. A hard-to-use pilot is quietly rigged toward producing a verdict of "no demand," and that manufactured verdict can then be used to justify never building the permanent program. Whether or not anyone intends it, friction becomes a mechanism for defeating a policy while appearing to let demand render the decision. The paperwork does not just block patients; it writes the conclusion.
What is fair to the other side
Some of the structure here is legitimate, and the underlying fiscal question is serious, both of which deserve saying plainly. These drugs are expensive, and Medicare has a real interest in confirming that they reach the patients who medically qualify and stand to benefit most, both to target them well and to contain what would otherwise be staggering costs. The eligibility checklist is not pure obstruction; it reflects genuine concerns about cost and appropriate use. The real question is whether the burden is calibrated to those goals or wildly overshoots them, and a physician on the front lines arguing it overshoots is worth taking seriously.
The decision to cancel permanent coverage, likewise, sits atop a genuine and contested debate. Covering these drugs for every eligible Medicare beneficiary could cost tens of billions of dollars a year, and reasonable people disagree about whether that is affordable or wise. This piece takes no position on that question. But the friction problem is separable from it, and it points to a neutral common ground that ought to hold regardless of where one stands: whatever you believe about whether Medicare should permanently cover GLP-1s, everyone should want the interim program's usage to reflect what people actually want rather than what they can bureaucratically endure, so that the permanent decision, whichever way it goes, rests on honest evidence instead of an artifact of the paperwork.
The physician who raised the alarm reached for the image of Venice's Bridge of Sighs, the passage that once carried prisoners toward resignation, and the metaphor turns out to be apter than it first looks. A bridge is useful only if people can cross it, and the design of this one may determine not just who reaches the far side but whether the far side is ever built. The deepest risk of a burdensome interim program is not only that it denies some qualifying patients a drug, painful as that is on its own. It is that the program quietly authors the evidence that will decide the permanent policy, and a program made hard enough to suppress its own use yields a verdict of no demand written by the process rather than by the patients. Whatever one concludes about the real and serious matter of whether Medicare can afford these drugs for millions of people, the interim test should measure what people genuinely want, not what they can survive bureaucratically. Otherwise the bridge leads nowhere, and the reason will be misread as no one having wished to cross.
Primary sources
- A STAT First Opinion essay by Jeffrey Millstein, an internist and regional medical director for primary and specialty care at Penn Medicine, for the details of Medicare's Bridge program, including the $50-per-month out-of-pocket cost for Wegovy, Zepbound, and Foundayo effective July 1, the eligibility checklist of BMI thresholds, chronic-condition combinations, and prior treatment histories, the documentation, prior-authorization, and appeals burden placed on primary care, the intended progression from Bridge to the permanent Balance program and the administration's cancellation of Balance and extension of Bridge through 2027, the warning that low uptake could be misread as limited demand rather than operational shortcoming, the risk of a two-tier system based on practices' administrative capacity, the observation that a benefit on paper differs from access in practice, the role of clinical pharmacists, and proposed fixes such as simplifying eligibility, reducing documentation, and eliminating unnecessary prior authorization.
- Related STAT reporting on the cancellation of Balance and on the uncertainty around the program's cost.
- The American College of Physicians journal and CMS Innovation Center materials referenced regarding the Bridge and Balance programs.
- General, well-established background on GLP-1 drugs, Medicare Part D, the statutory exclusion of weight-loss drugs, primary-care workforce strain, and the cost debate over broad coverage.